The edoxaban-M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma.

As shown in Figure 5 and in Table S1 , we observed an increasing trend between the M4/edoxaban ratio and the difference measured between the chromogenic and chromatographic method. 4 DISCUSSION Although routine monitoring is generally not required for the direct FXa (i.e., apixaban, rivaroxaban, and edoxaban) and FIIa (dabigatran) inhibitors because of predictable pharmacokinetic and pharmacodynamic profiles, it should be considered for edoxaban, owing to physiologically active metabolites (M4, M6, and M8), especially in the case of drug‐drug interactions or physiological impairment such as renal or hepatic insufficiency.

also in 63,971 other papers